Related Experiment Video
Updated: Mar 13, 2026

Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease
Published on: April 17, 2017
Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease
Matthias Boentert1, Hélène Prigent2, Katalin Várdi3
1Department of Sleep Medicine and Neuromuscular Disorders, Münster University Hospital, Münster 48149, Germany. matthias.boentert@ukmuenster.de.
Insights
Pompe disease causes progressive muscle weakness, particularly affecting breathing. Early detection and management of respiratory issues are vital for improving survival in late-onset Pompe disease patients.
Area of Science:
- Neurology
- Pulmonology
- Genetics
Background:
- Pompe disease is a genetic disorder causing progressive muscle weakness.
- Respiratory muscle dysfunction is a significant complication in late-onset Pompe disease.
- Weakness impacts breathing, cough, and increases infection risk.
Purpose of the Study:
- To provide expert recommendations for diagnosing and managing respiratory muscle involvement in late-onset Pompe disease.
- To highlight the critical need for multidisciplinary care in managing respiratory complications.
Main Methods:
- Review of clinical experience with over 200 patients.
- Development of practical guidelines for respiratory care.
Main Results:
- Respiratory muscle weakness can progress faster than other neurological deficits.
- Sleep-disordered breathing, hypercapnia, and ventilation needs are common.
- Respiratory compromise is a major cause of mortality despite treatment.
Conclusions:
- Effective management of respiratory muscle weakness is crucial for Pompe disease patient outcomes.
- A collaborative approach involving neurologists, pulmonologists, and intensivists is essential.
- Early detection and intervention improve patient care and survival.
Abstract:
Pompe disease is an autosomal-recessive lysosomal storage disorder characterized by progressive myopathy with proximal muscle weakness, respiratory muscle dysfunction, and cardiomyopathy (in infants only). In patients with juvenile or adult disease onset, respiratory muscle weakness may decline more rapidly than overall neurological disability. Sleep-disordered breathing, daytime hypercapnia, and the need for nocturnal ventilation eventually evolve in most patients. Additionally, respiratory muscle weakness leads to decreased cough and impaired airway clearance, increasing the risk of acute respiratory illness. Progressive respiratory muscle weakness is a major cause of morbidity and mortality in late-onset Pompe disease even if enzyme replacement therapy has been established. Practical knowledge of how to detect, monitor and manage respiratory muscle involvement is crucial for optimal patient care. A multidisciplinary approach combining the expertise of neurologists, pulmonologists, and intensive care specialists is needed. Based on the authors' own experience in over 200 patients, this article conveys expert recommendations for the diagnosis and management of respiratory muscle weakness and its sequelae in late-onset Pompe disease.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Cardiomyopathy VI: Nursing Management
Acute Respiratory Failure-III
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

